Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

»ïÂ÷½Å°æ ¼Õ»ó¿¡ ÀÇÇÑ ½Å°æº´Áõ¼º ÅëÁõ¿¡¼­ º¸Åø¸®´® µ¶¼ÒÀÇ ÁøÅë È¿°ú

Analgesic Effect of Botulinum Toxin on Neuropathic Pain after Trigeminal Nerve Injury

±¸°­È¸º¹ÀÀ¿ë°úÇÐÁö 2012³â 28±Ç 2È£ p.171 ~ 178
±è¿µ°Ç, ±è¼ºÅÃ,
¼Ò¼Ó »ó¼¼Á¤º¸
±è¿µ°Ç ( Kim Young-Gun ) - ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­³»°úÇб³½Ç
±è¼ºÅà( Kim Seong-Taek ) - ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­³»°úÇб³½Ç

Abstract

º¸Åø¸®´® µ¶¼Ò ÁÖ»ç´Â À̸¶, ´«°¡ ÁÖ¸§Ä¡·á µî ¹Ì¿ë¼ºÇüºÐ¾ß »Ó¸¸ ¾Æ´Ï¶ó ±¸°­ ¾Ç¾È¸é ºÐ¾ß¿¡¼­´Â ¸¸¼º ÆíµÎÅë(chronic migraine), ±ÙÀ°±äÀåÀÌ»ó(dystonia), °æÁ÷(spasticity), ÃøµÎÇϾÇÀå¾Ö (temporomandibular disorders, TMD)ÀÇ Ä¡·á µî¿¡ »ç¿ëµÇ¾î ¿Ô´Ù. ÃÖ±Ù º¸Åø¸®´® µ¶¼Ò Áֻ簡 ¿îµ¿½Å°æ¿¡¼­ ¸¶ºñÈ¿°ú »Ó¸¸ ¾Æ´Ï¶ó °¨°¢½Å°æ¿¡¼­ ¸»ÃÊ°¨ÀÛ°ú ½Å°æ¿ø¼º¿°Áõ°ú °ü·ÃµÇ´Â substance P, CGRP, glutamate µî ºñÄݸ°¼º ½Å°æÀü´Þ¹°ÁúÀÇ À¯¸®¸¦ Â÷´ÜÇÏ¿© ÅëÁõ½ÅÈ£¸¦ Â÷´ÜÇÏ´Â ¿ªÇÒÀ» ÇÑ´Ù´Â °¡¼³ÀÌ Á¦±âµÇ°í ÀÖ´Ù. µû¶ó¼­ º» ¿¬±¸´Â Áã, Åä³¢ µî µ¿¹° ½Å°æ ¼Õ»ó ¸ðµ¨¿¡ ´ëÇÑ ½ÇÇè°ú Ä¡°ú Ä¡·á ÈÄ ¹ß»ýÇÑ ½Å°æ ¼Õ»ó ȯÀÚ¿¡¼­ º¸Åø¸®´® µ¶¼ÒÀÇ ÁøÅë È¿°ú ¹× ÀÛ¿ë ±âÀüÀ» »ìÆ캸°íÀÚ ÇÑ´Ù.

Botulinum toxin type A (BoNT-A) has been applied successfully to treat chronic migraine, dystonia, spasticity and
temporomandubular disorders(TMDs) as well as frontal wrinkle and glabella wrinkle. Recently it has been reported that
BoNT-A, reversibly blocks presynaptic acetylcholine release, also inhibits the release of substance P, CGRP(calcitonin gene related peptide) and glutamate related to peripheral sensitization and neurogenic inflammation in sensory nerve, In this study we reviewed animal nerve injury model such as rat and rabbit and identify the analgesic effect and mechanism of nerve injury pain after dental treatment.

Å°¿öµå

º¸Åø¸®´® µ¶¼Ò;ÅëÁõ;½Å°æ¼Õ»ó
botulinum toxin;pain;nerve injury

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI